Impressive how Chai-2 is tackling full-length mAbs rather than just fragments. The 86% success rate on preclinical criteria is solid, but the real test will be how those cryo-EM-validated structures actually perfrom in vivo. I've seen too many computationally-designed binders fail once they hit wet lab conditions. Still, if they can really push targets like GPCRs and peptide-MHC complexes with such low candidate counts, that changes the economics of early discovery substantially.
Impressive how Chai-2 is tackling full-length mAbs rather than just fragments. The 86% success rate on preclinical criteria is solid, but the real test will be how those cryo-EM-validated structures actually perfrom in vivo. I've seen too many computationally-designed binders fail once they hit wet lab conditions. Still, if they can really push targets like GPCRs and peptide-MHC complexes with such low candidate counts, that changes the economics of early discovery substantially.
Spot on, indeed. Let's see how Chai delivers further milestones in 2026